LABORIE Announces Exclusive Distribution Agreement With Uromedica, Inc. In France And Switzerland
LABORIE has entered into a distribution agreement effective today with Uromedica, Inc. to distribute its ACT and ProACT devices in France and Switzerland.
- (1888PressRelease) January 19, 2011 - LABORIE, a leading marketer of medical devices in urology and gynecology, has entered into a distribution agreement effective today with Uromedica, Inc. to distribute its ACT and ProACT devices in France and Switzerland.
LABORIE is pleased to partner with Uromedica and distribute the Adjustable Continence Therapies (ACT® and ProACT™) for patients with unmet medical needs in the area of urogenital and related disorders. LABORIE will make these therapies available to healthcare professionals, patients and LABORIE's customers in these two respective countries.
ACT and ProACT devices are the only minimally invasive, non-destructive, reversible and adjustable therapies available for male and female patients with stress urinary incontinence (SUI). To date, over 10,000 patients have been implanted with this minimally invasive device throughout the world with long term efficacy.
"ACT and ProACT are already well-known devices used by our customers and LABORIE is proud to market Uromedica's innovative devices" said Arnaud Mejean, Vice-President of Global Marketing. "LABORIE will work with the scientific communities to expand the availability of these innovative devices and reflect LABORIE's ongoing commitment towards Innovation for Pelvic Health".
Tim Cook, PhD, founder of Uromedica stated "Uromedica is very pleased to be working with the LABORIE organization, they are well recognized as the leading provider of the finest urodynamic instrumentation and I expect our collaboration to be successful in providing strong support to the urologic and gynecologic communities and the SUI patient population."
About LABORIE
LABORIE is a leading multinational developer, manufacturer and marketer of innovative medical equipment and catheters in urology and gynecology for the diagnosis and treatment of incontinence, pelvic organ prolapse and pain.
For more information regarding LABORIE and their line of products, please visit www.laborie.com
About Uromedica, Inc.
Uromedica, Inc. was formed in 1997 to develop minimally invasive medical devices that treat unmet medical needs in the area of urogenital and related disorders. Developed by Uromedica and awarded the CE mark in 2002, ACT® (Adjustable Continence Therapy) and ProACT™ treat stress urinary incontinence. ACT and ProACT are not commercially available in the United States. www.uromedica-inc.com
About ACT and ProACT.
The Adjustable Continence Therapy (ACT®) system consists of an inflatable balloon connected to a subcutaneous filling port. Once implanted, the device can be post-operatively adjusted through the skin with a small gauge needle in an office setting with no further surgery. Based upon the patient's individual needs, fluid can be added or withdrawn from the balloon via the subcutaneous filling port either during the surgery or years later. This makes the ACT and ProACT devices the only minimally invasive, non-destructive, reversible and adjustable therapies available for male and female patients with stress urinary incontinence (SUI).
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam